The Leona M. and Harry B. Helmsley Charitable Trust

Thetis Pharmaceuticals LLC is a biopharmaceutical company based in Branford, Connecticut, founded in 2011. The company focuses on developing immuno-resolving therapeutic solutions aimed at treating inflammatory bowel diseases and other inflammatory conditions. Utilizing its proprietary HEALER technology platform, Thetis Pharmaceuticals creates novel small molecule drugs that leverage the pharmacological properties of lipids to promote tissue regeneration and manage inflammation effectively. The company's research has yielded resolvins, which are potent agonists designed to facilitate inflammation resolution and tissue repair. These therapies aim to help healthcare professionals regulate the body's inflammatory response without compromising immune function, addressing the challenges associated with overactive inflammation in various diseases.

TIXiMED is a biotechnology company focused on the development and commercialization of oral therapeutics for the treatment of Type 1 and Type 2 diabetes. The company aims to provide innovative solutions that help manage diabetes effectively by lowering glucagon levels and inhibiting glucose production in the liver. TIXiMED's approach seeks to reduce the need for multiple daily insulin injections and continuous insulin infusions, thereby enhancing the quality of life for diabetic patients and potentially lowering their overall treatment costs. In addition to diabetes, the company is also engaged in addressing non-alcoholic fatty liver disease (NAFLD), further expanding its commitment to improving health outcomes for individuals affected by these conditions.

The Mount Sinai School of Medicine in New York, New York, one of the only schools in the nation with a distinctive Department of Medical Education that continually improves the quality of its teaching, offers students a variety of medical academics to shape them into compassionate assistants, professionals and industry leaders. The academics available at Mount Sinai include master's and PhD programs in areas like: * Science and Medicine * Patient Oriented Research Training and Leadership * Biomedical Sciences * Genetic Counseling * Clinical Research Besides its degree-granting programs, Mount Sinai also offers an extensive number of residencies and fellowships, some of which include: * Anesthesiology * Cardiology * Dental Medicine * Emergency Medicine * Hematology and Oncology College life at Mount Sinai is fully-immersed in the medical sciences. All your instruction, provided by medical professionals, will be delivered in a hospital setting, allowing you to familiarize yourself with the many resources and technology used in today's hospitals. Mount Sinai is also home to the Levy Library, which is fully-stocked with myriad medical resources, from journals to professional magazines to textbooks. Since each program has different admissions requirements, please contact Mount Sinai for more information on a program that interests you and your career goals. Tuition assistance is available to students through fellowship programs and Mount Sinai grants and scholarships. For more information federal sources of financial aid, please contact an aid advisor from the school.

NYC Health + Hospitals provides health care services. They provide dental care, depression care, diabetes care, abortion care, and smoking cessation services. The corporation operates a network of hospitals, community-based health clinics, long-term care, and rehabilitation facilities, home care services, correctional health services, and MetroPlus, a health plan.

Brigham and Women's Hospital is a leading medical institution located in Boston, Massachusetts, and serves as one of Harvard Medical School's major teaching affiliates, featuring 793 beds. As a founding member of Partners HealthCare, it represents the largest healthcare provider in the state. The hospital specializes in various areas including cancer care, heart and vascular treatments, neurology, and women's health, among others, aiming to enhance patient outcomes through comprehensive medical services. Brigham and Women’s Hospital is also dedicated to advancing biomedical research and education, hosting numerous training programs for healthcare professionals. Recognized as the second largest NIH-funded hospital in the United States, it is known for its innovative contributions to medicine, including advancements in organ transplantation and cardiovascular surgery. The facility offers modern inpatient care and a wide array of outpatient services, ensuring continuity of care through community health centers and cutting-edge diagnostic and treatment facilities in multiple countries, while upholding a commitment to health equity and reducing disparities in healthcare.

Thetis Pharmaceuticals LLC is a biopharmaceutical company based in Branford, Connecticut, founded in 2011. The company focuses on developing immuno-resolving therapeutic solutions aimed at treating inflammatory bowel diseases and other inflammatory conditions. Utilizing its proprietary HEALER technology platform, Thetis Pharmaceuticals creates novel small molecule drugs that leverage the pharmacological properties of lipids to promote tissue regeneration and manage inflammation effectively. The company's research has yielded resolvins, which are potent agonists designed to facilitate inflammation resolution and tissue repair. These therapies aim to help healthcare professionals regulate the body's inflammatory response without compromising immune function, addressing the challenges associated with overactive inflammation in various diseases.

Shamir Medical Centre is an advanced clinic for twin mothers whose pregnancies will receive tests outside of the health basket at no cost, such as a non-invasive blood test for chromosomal abnormalities, a preeclampsia test, a screening test to find and prevent premature birth, along with a variety of other recognized tests during pregnancy, like the nuchal test. The clinic offers one-on-one or group parent education. The sessions will be held without the kids present.

Beyond Type 1 is a nonprofit organization changing what it means to live with diabetes. Through platforms, programs, resources, and grants, Beyond Type 1 is uniting the global diabetes community and providing solutions to improve lives today. Founded in 2015 with a focus on education, advocacy and the path to a cure for Type 1 diabetes, Beyond Type 1 has grown to also include programs for those with Type 2 diabetes.

The University of Massachusetts Medical School (UMMS), founded in 1962 and located in Worcester, Massachusetts, is dedicated to providing affordable, high-quality medical education with a focus on increasing the number of primary care physicians in underserved areas. The institution aims to advance health and wellness in diverse communities both locally and globally through its commitment to education, research, healthcare delivery, and public service. Consistently recognized as a leading medical school for primary care education, UMMS plays a vital role in shaping healthcare professionals and addressing public health challenges.

Capillary Biomedical, Inc. is a medical device company based in Irvine, California, established in 2014 as a spin-out from the Artificial Pancreas Center at the Sidney Kimmel Medical College. The company focuses on developing innovative technologies for diabetes management, aiming to simplify the processes of glucose monitoring and insulin delivery. Their signature product features a kink-proof, flexible, multiport cannula designed to enhance the reliability and comfort of insulin delivery. This user-friendly device allows for simple one-handed insertion, enabling diabetes patients to better manage their blood glucose levels and alleviating some of the burdens associated with diabetes on both individuals and the healthcare system.

DreaMed Diabetes, Ltd. is an Israel-based company founded in 2014 that specializes in developing innovative solutions for diabetes treatment and management. The company has created a portfolio that includes Glucositter, a closed-loop insulin delivery system designed to monitor glucose levels in real-time and optimize insulin adjustments. DreaMed Diabetes is recognized for commercializing the first artificial pancreas technology, which has been validated in leading medical journals. It has also pioneered decision support tools for diabetes management, being the first company to receive FDA clearance for a system utilizing data from continuous glucose monitors and insulin pumps. Its Advisor Pro software, developed by diabetes professionals, leverages artificial intelligence to enable healthcare providers to quickly analyze patient data and recommend personalized treatment plans. Through frequent insulin titration and online monitoring, DreaMed Diabetes aims to enhance patient care by reducing A1C levels and the risk of complications, ensuring that all patients receive high-quality treatment regardless of their location or caregiver.

Tidepool is a United States-based company that provides an analytics platform focused on enhancing the management of diabetes data. By making this data more accessible, actionable, and meaningful, Tidepool aims to improve the experiences of individuals with diabetes, their care teams, and researchers. The company employs advanced scientific techniques and patented technology to offer insights that help users understand how their psychological characteristics, including personality, thinking, and mood, impact daily performance. Users can engage with Tidepool through fun, interactive games that facilitate self-assessment and allow for daily tracking. Future developments will enable integration with various quantified self devices, enhancing the platform's utility for users.

Biorasis, established in December 2007, focuses on the development of needle-implantable biosensors designed for real-time, continuous monitoring of bio-analytes. Initially aimed at commercializing a miniaturized sensor platform for glucose monitoring in diabetes management, the company is expanding its technology to track additional bio-analytes related to various medical conditions, including cardiovascular diseases, cancer, liver and kidney abnormalities, stroke, and epilepsy. Biorasis's innovative approach not only facilitates effective metabolic monitoring but also aims to minimize tissue damage during the implantation process, enhancing patient care and supporting drug research and development.

Beginning in 1993, Avera offered eCARE Specialty Clinic services to rural, frontier and critical access hospitals that were part of the Avera Health system. Ten years later, Avera eCARE expanded to provide eCARE ICU, the first 24-hour, on-demand service that allows staff at partner facilities to connect virtually via a video and audio call for immediate assistance from board-certified providers. In addition, Avera eCARE delivered 24/7 access to a wide range of medical specialists and referrals to specialty care for a growing number of underserved populations and communities. Then, in 2009, through a grant from The Leona M. and Harry B. Helmsley Charitable Trust, Avera eCARE launched eCARE Emergency and eCARE Pharmacy for all of Avera’s rural hospitals. Additional funding from the Helmsley Charitable Trust and other sources allowed expansion to over 200 Avera facilities across eight states and the ability to serve partners outside Avera Health. By 2012, Avera eCARE services were available for long-term care and correctional facilities. At Avera eCARE, their telemedicine professionals work together 24/7 in the eHELM, their virtual hospital hub, also created in 2012 with the assistance of the Helmsley Charitable Trust. By staffing their central facility around the clock, their partners and patients benefit from the multidisciplinary collaboration of medical specialists within their telemedicine teams 24/7/365.

Zucara Therapeutics Inc. is a biotechnology company focused on developing innovative therapeutics to prevent hypoglycemia, or low blood sugar, in patients with diabetes. Established in 2014 and headquartered in Toronto, Canada, with an additional office in Vancouver, Zucara is pioneering a once-daily treatment that aims to regulate the hormone somatostatin in the pancreas. This treatment specifically targets somatostatin type 2 receptors, which are not effectively controlled in patients with Type 1 diabetes. Zucara's approach presents a significant advancement in diabetes care by functioning as a preventative measure against hypoglycemia, contrasting with existing therapies that only provide rescue during acute episodes. Through its pre-clinical technology, Zucara Therapeutics aims to restore natural glucose levels in the blood, ultimately enhancing the quality of life for individuals living with diabetes.

Cody Regional Health is focusing on putting the patient first. Located in Cody, Wyo., their hospital serves as a primary, full-service medical center to communities throughout the Big Horn Basin. They also have an adjacent Long Term Care Center licensed for 94 beds and a 20-bed chemical dependency center. The Hospital has adopted the Planetree philosophy as a model of health care. The Planetree model strives to enhance patient comfort by personalizing, humanizing and demystifying the health care experience.

Beyond Type 1 is a nonprofit organization changing what it means to live with diabetes. Through platforms, programs, resources, and grants, Beyond Type 1 is uniting the global diabetes community and providing solutions to improve lives today. Founded in 2015 with a focus on education, advocacy and the path to a cure for Type 1 diabetes, Beyond Type 1 has grown to also include programs for those with Type 2 diabetes.

Salk Institute for Biological Studies conducts research on molecular biology and genetics, neurosciences, and plant biology. The research is conducted under the guidance of 59 faculty investigators and more than 850 scientific staff, including visiting scientists, postdoctoral fellows, and graduate students. The institute’s operates to identify therapies and treatments for a range of diseases such as cancer, AIDS, Alzheimer's disease, cardiovascular disorders, anomalies of the brain, and birth defects. Six key areas represent strategic research priorities: chemistry and proteomics, stem cell biology, cell biology, regulatory biology, metabolic research, and computational and theoretical biology. The Institute has trained more than 2,700 scientists, out of which five have won Nobel prizes. Salk is home to nine Howard Hughes Medical Investigators and 14 members of the National Academy of Sciences. NCI Cancer Center, Crick-Jacobs Center, Glenn Center for Aging Research, Helmsley Center for Genomic Medicine, Waitt Advanced Biophotonics Center, and Glenn Center for Aging Research are some of the research centers operated by Salk Institute for Biological Studies. The Salk Institute for Biological Studies was established in the 1960s by Jonas Salk and is based in California, United States.